

CWSCS 14 SEP 2004

**FAX**

Date: September 13, 2004
To: Office of Initial Patent Examination's Filing Receipt Corrections
Application #: 10/812,143
Filing Date: 03/29/04
Fax Number: 703-746-9195
From: Rachel A. Polster
cc:
Pages: 2 (including cover sheet)

Pfizer Inc
575 Maryville Centre Drive
St. Louis, Missouri 63141
tel 314.274.7354
fax 314.274.9095
rachel.a.polster@pfizer.com
www.pfizer.com

The attached filing receipt shows our Power of Attorney customer number as 23913; however, the customer number at this St. Louis site is 26648. Applicant requests a corrected customer number for this application. Formal documentation will be mailed at a later date.

A handwritten signature of Rachel A. Polster.

Rachel A. Polster
47,004

Confidentiality Note: The documents accompanying this telex/copy transmission contain information belonging to Pfizer Inc, which is intended only for the use of the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telexed/copied information is strictly prohibited. If you have received this telex/copy in error, please immediately notify us by telephone to arrange for the return of the original documents to us.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/812,143	03/29/2004	1626	900	R002037B		1	1

RECEIVED

26648
 PHARMACIA CORPORATION
 GLOBAL PATENT DEPARTMENT
 POST OFFICE BOX 1027
 ST. LOUIS, MO 63006

SEP 07 2004

PHARMACIA
 GLOBAL PATENT DEPT.
 ST. LOUIS, MO

CONFIRMATION NO. 3239

UPDATED FILING RECEIPT




OC000000013694607

Date Mailed: 09/01/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9196. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Charlotte Moira Norfor Allerton, Residence Not Provided;
 David John Bull, Residence Not Provided;
 Mark Edward Bunnage, Residence Not Provided;
 Robert John Maguire, Residence Not Provided;
 John Steele, Residence Not Provided;



Assignment For Published Patent Application

Pfizer Inc., New York, NY

Power of Attorney: The patent practitioners associated with Customer Number 23913-26648.

Domestic Priority data as claimed by applicant

This application is a DIV of 10/348,881 01/22/2003 PAT 6,713,496
 which claims benefit of 60/362,377 03/06/2002

Foreign Applications

UNITED KINGDOM 0201389.4 01/22/2002
 UNITED KINGDOM 0202027.9 01/29/2002

If Required, Foreign Filing License Granted: 06/08/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/812,143